The document discusses how pharmaceutical companies can satisfy both return on investment (ROI) and FDA regulations through social media. It summarizes the evolution of FDA guidance on social media and how marketing ROI has shifted from measuring outputs to outcomes and impact. The document also provides examples of how pharmaceutical companies have successfully built social media presences that increased patient engagement and community while meeting FDA requirements.